αααααβααΎαFMS β’ NYSE
add
Fresenius Medical Care AG
28.63$
αααααααααα(0.00%)0.00
28.63$
ααΆααα·αα 9 αα·αα»ααΆ, 5:03:01 PM ααααβααα -4 · USD · NYSE · ααα
ααααΈαααααΆααα·αααα½ααα»αααααΌα
αα·αααΈαα»α
28.51$
α
αααααααααααα
28.37$ - 28.72$
α
ααααααα½αααααΆαα
α»αααααα
17.93$ - 30.46$
ααΎαβαα»αβααΈααααΆα
16.89Β αααΈααΆα USD
ααα ααα½αααΌαααααα
519.12Β ααΆαα
ααααααΆαααΈααααΆα
α α·ααααααααα»
αααΆαααΆαααααααΆααα
αααΌα
α
αααΌα
α
αααΌααα»ααα
(EUR) | ααΈααΆ 2025info | ααΆαααααΆααααααΌαααΆαβααααΆα |
---|---|---|
α
αααΌα | 4.88Β αααΈααΆα | 3.32% |
α
αααΆαααααα·ααααα·ααΆα | 802.25Β ααΆα | -1.22% |
α
αααΌααα»ααα | 151.22Β ααΆα | 113.11% |
ααααΆααα
αααααα»ααα | 3.10 | 106.67% |
βα
αααΌααα»αααβαααα»ααα½αααΆαα αα»α | 0.42 | -34.54% |
α
αααΌααα»ααααα»αααΆαααααΆαα αααα ααΆαααααα αα·αααΆαααΆααααααα | 764.32Β ααΆα | 2.02% |
α’ααααΆαααααααααΆαααααα·αααααΆα | 24.35% | β |
αααααΈαααα»ααα
ααααααααα»α
ααΆαααα½ααα»αααααΌαααα»α
(EUR) | ααΈααΆ 2025info | ααΆαααααΆααααααΌαααΆαβααααΆα |
---|---|---|
ααΆα
αααααΆαα αα·αααΆααα·αα·αααααααααααααΈ | 1.07Β αααΈααΆα | -6.70% |
ααααααααα»α | 32.74Β αααΈααΆα | -4.66% |
ααΆαααα½ααα»αααααΌαααα»α | 17.23Β αααΈααΆα | -10.28% |
ααΌαβααααα»α | 15.50Β αααΈααΆα | β |
ααΆαα αα»αβαα·αβααΆααααΆαααα | 293.41Β ααΆα | β |
ααααααααααΉαααααα
| 0.58 | β |
ααα
ααααααΎαααααα | 2.88% | β |
ααα
ααααααΎααΎααα»α | 3.59% | β |
ααα αΌαβααΆα
αβααααΆααβ
ααΆααααααααα½αβααΆα
αααααΆαααα»ααα
(EUR) | ααΈααΆ 2025info | ααΆαααααΆααααααΌαααΆαβααααΆα |
---|---|---|
α
αααΌααα»ααα | 151.22Β ααΆα | 113.11% |
ααΆα
αααααΆααααΈααααα·ααααα·ααΆα | 162.82Β ααΆα | 27.90% |
ααΆα
αααααΆααααΈααΆααα·αα·ααα | -108.24Β ααΆα | -58.32% |
ααΆα
αααααΆααααΈα α·ααααβαααααΆα | -138.79Β ααΆα | 52.09% |
ααΆααααααααα½αβααΆα
αααααΆαααα»ααα | -106.64Β ααΆα | 54.67% |
ααα αΌαααΆα
αααααΆααααααα | -195.05Β ααΆα | 56.02% |
α’αααΈ
Fresenius Medical Care AG & Co. KGaA is an American-German healthcare company which provides kidney dialysis services through a network of 4,171 outpatient dialysis centers, serving 345,425 patients. The company primarily treats end-stage renal disease, which requires patients to undergo dialysis 3 times per week for the rest of their lives.
With a global headquarters in Bad Homburg vor der HΓΆhe, Germany, and a North American headquarters in Waltham, Massachusetts, it has a 38% market share of the dialysis market in the United States. It also operates 42 production sites, the largest of which are in the U.S., Germany, and Japan.
The company is 32% owned by Fresenius and, as of 2020, generates around 50% of the group's revenue.
The company is on the Best Employers List published by Forbes. Wikipedia
CEO
ααΆααααααΎαα‘αΎα
1996
αααααβαααααΆα
αα»ααααα·α
112,035